Montero M;VanScoy BD;López-Causapé C;Conde H;Adams J;Segura C;Zamorano L;Oliver A;Horcajada JP;Ambrose PG, "Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa ST175 in a Hollow-Fiber Infection Model", "Antimicrobial Agents and Chemotherapy", 2018. Article en premsa.
Fraile-Ribot PA;Cabot G;Mulet X;Periañez L;Martín-Pena ML;Juan C;Pérez JL;Oliver A, "Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa", "Journal of Antimicrobial Chemotherapy", Volum 73, Número 3, Pàgines 658-663, 2018. Article.
López-Causapé C;Rubio R;Cabot G;Oliver A, "Evolution of the Pseudomonas aeruginosa aminoglycoside mutational resistome in vitro and in the cystic fibrosis setting", "Antimicrobial Agents and Chemotherapy", Volum 32, Número 1, Pàgines 78-100, 2018. Article.
Landersdorfer CB;Rees VE;Yadav R;Rogers KE;Kim TH;Bergen PJ;Cheah SE; Boyce JD;Peleg AY;Oliver A;Shin BS;Nation RL;Bulitta JB, "Optimization of a meropenem plus tobramycin combination dosage regimen against hypermutable and non-hypermutable Pseudomonas aeruginosa via mechanism-based modeling and the hollow-fiber infection model", "Antimicrobial Agents and Chemotherapy", 2018. Article en premsa.
Celenza G;Vicario M;Bellio P;Linciano P;Perilli M;Oliver A;Blazquez J; Cendron L;Tondi D, "Phenylboronic Acid Derivatives as Validated Leads Active in Clinical Strains Overexpressing KPC-2: A Step against Bacterial Resistance", "ChemMedChem", 2018. Article en premsa.